Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first event in an R&D "Teach-in" webinar series that will provide deeper insights on the company's differentiated product pipeline, which was unveiled in November 2025.

On Monday, March 23, 2026, at 1:30 p.m. ET, Executive Vice President of Research & Development and Chief Medical Officer Yehia Hashad, MD, will be joined by members of his leadership team to discuss two glaucoma assets:

BL1107, a glaucoma medication under development that would be the first to treat vision loss in addition to lowering intraocular pressure
ELIOS^™, an implant-free minimally invasive glaucoma surgery approach using excimer laser precision to create outflow channels safely and effectively; already commercialized in Europe and backed by extensive clinical data (anticipated U.S. launch: 2H 2026)

Chairman and CEO Brent Saunders, Executive Vice President and Chief Financial Officer Sam Eldessouky and Global Pharmaceuticals and International Consumer President Andrew Stewart will also participate.

Registration for the live webinar hosted by Wells Fargo as part of its Innovation Spotlight series can be accessed here. Following the event, a replay will be available on the Investor Relations page of the Bausch + Lomb website.

About Bausch + Lomb

Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we've evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we're turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260309768376/en/

Media Contact:

Chris Clark

chris.clark@bausch.com

(848) 360-1100

Investor Contact:

George Gadkowski

george.gadkowski@bausch.com

(877) 354-3705 (toll free)